Genetic medicines company enGene Holdings (Nasdaq: ENGN) has named Ron Cooper (pictured, above) its new chief executive.
This transition follows a previously announced succession plan for Jason Hanson, who will remain a strategic advisor to the company, which is conducting a pivotal study with its non-viral, intravesical lead product candidate, EG-70, in BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC).
Mr Cooper most recently served as president and chief executive of Albireo Pharma, a fully integrated global commercial biopharmaceutical company that Ipsen (Euronext: IPN) acquired in 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze